{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:01:40Z","timestamp":1784070100489,"version":"3.55.0"},"reference-count":73,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The rates of uncontrolled hypertension, along with downstream cardiovascular outcomes, has been worsening in this country. Despite the plethora of antihypertensive medications on the market, the prevalence of resistant hypertension (RH) is estimated to be 13.7%. Therefore in addition to increased clinical education and focus on lifestyle management of hypertension and medication compliance, new therapies are needed to address this rise in hypertension.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A systematic review of the available medical literature was performed to identify emerging treatment options for RH.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Six different pharmacologic classes and 2 procedural interventions were identified as being appropriate for review in this paper. The pharmacologic classes to be explored are non-steroidal mineralocorticoid receptor antagonists, aminopeptidase A inhibitors, dual endothelin antagonists, aldosterone synthetase inhibitors, atrial natriuretic peptide inhibitors, and attenuators of hepatic angiotensinogen. Discussion of procedural interventions to lower blood pressure will focus on renal denervation and devices that increase carotid baroreceptor activity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Promising medication and procedural interventions are being developed and studied to expand our treatment arsenal for patients with uncontrolled essential hypertension and RH.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajh\/hpac111","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T17:07:23Z","timestamp":1665076043000},"page":"73-81","source":"Crossref","is-referenced-by-count":13,"title":["Novel Therapies on the Horizon of Hypertension Management"],"prefix":"10.1093","volume":"36","author":[{"given":"Olivia","family":"Blazek","sequence":"first","affiliation":[{"name":"Department of Medicine, American Heart Association Comprehensive Hypertension Center, University of Chicago Medicine , Chicago, IL 60637 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1183-1267","authenticated-orcid":false,"given":"George L","family":"Bakris","sequence":"additional","affiliation":[{"name":"Department of Medicine, American Heart Association Comprehensive Hypertension Center, University of Chicago Medicine , Chicago, IL 60637 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"2023021305292034600_CIT0001","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"2023021305292034600_CIT0002","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics-2022 Update: a report from the American Heart Association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"2023021305292034600_CIT0003","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jama.2020.14545","article-title":"Trends in blood pressure control among US adults with hypertension, 1999-2000 to 2017-2018","volume":"324","author":"Muntner","year":"2020","journal-title":"JAMA"},{"key":"2023021305292034600_CIT0004","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant Hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"2023021305292034600_CIT0005","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12882-019-1315-0","article-title":"Resistant hypertension and cardiovascular disease mortality in the US: results from the National Health and Nutrition Examination Survey (NHANES)","volume":"20","author":"Kaczmarski","year":"2019","journal-title":"BMC Nephrol"},{"key":"2023021305292034600_CIT0006","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ki.2011.48","article-title":"Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease","volume":"79","author":"Bertocchio","year":"2011","journal-title":"Kidney Int"},{"key":"2023021305292034600_CIT0007","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1146\/annurev-physiol-060821-013950","article-title":"Roles of mineralocorticoid receptors in cardiovascular and cardiorenal diseases","volume":"84","author":"Barrera-Chimal","year":"2022","journal-title":"Annu Rev Physiol"},{"key":"2023021305292034600_CIT0008","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1046\/j.1523-1755.2000.00965.x","article-title":"Mineralocorticoid receptor knockout mice: lessons on Na+ metabolism","volume":"57","author":"Berger","year":"2000","journal-title":"Kidney Int"},{"key":"2023021305292034600_CIT0009","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S2213-8587(15)00289-2","article-title":"Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism","volume":"3","author":"Epstein","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023021305292034600_CIT0010","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/sj.ki.5000438","article-title":"Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats","volume":"70","author":"Han","year":"2006","journal-title":"Kidney Int"},{"key":"2023021305292034600_CIT0011","doi-asserted-by":"crossref","first-page":"F1381","DOI":"10.1152\/ajprenal.00101.2009","article-title":"Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions","volume":"297","author":"Lee","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"2023021305292034600_CIT0012","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1681\/ASN.2008020232","article-title":"Aldosterone activates NF-kappaB in the collecting duct","volume":"20","author":"Leroy","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2023021305292034600_CIT0013","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"2023021305292034600_CIT0014","first-page":"CD007004","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2023021305292034600_CIT0015","first-page":"CD007004","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"4","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2023021305292034600_CIT0016","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","article-title":"Prediction and management of hyperkalemia across the spectrum of chronic kidney disease","volume":"34","author":"Lazich","year":"2014","journal-title":"Semin Nephrol"},{"key":"2023021305292034600_CIT0017","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1097\/HJH.0000000000002187","article-title":"Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Alexandrou","year":"2019","journal-title":"J Hypertens"},{"key":"2023021305292034600_CIT0018","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1111\/bph.15747","article-title":"Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"179","author":"Kintscher","year":"2022","journal-title":"Br J Pharmacol"},{"key":"2023021305292034600_CIT0019","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2023021305292034600_CIT0020","doi-asserted-by":"crossref","first-page":"105859","DOI":"10.1016\/j.phrs.2021.105859","article-title":"Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy","volume":"172","author":"Kolkhof","year":"2021","journal-title":"Pharmacol Res"},{"key":"2023021305292034600_CIT0021","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2023021305292034600_CIT0022","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41371-019-0207-x","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study","volume":"33","author":"Ito","year":"2019","journal-title":"J Hum Hypertens"},{"key":"2023021305292034600_CIT0023","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10157-020-01963-z","article-title":"Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study","volume":"25","author":"Wada","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"2023021305292034600_CIT0024","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"key":"2023021305292034600_CIT0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"key":"2023021305292034600_CIT0026","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","article-title":"Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist","volume":"761","author":"Arai","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"2023021305292034600_CIT0027","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41371-020-0377-6","article-title":"Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease","volume":"35","author":"Wan","year":"2021","journal-title":"J Hum Hypertens"},{"key":"2023021305292034600_CIT0028","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1124\/jpet.116.234765","article-title":"CS-3150, a Novel Nonsteroidal mineralocorticoid receptor antagonist, shows preventive and therapeutic effects on renal injury in deoxycorticosterone acetate\/salt-induced hypertensive rats","volume":"358","author":"Arai","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"2023021305292034600_CIT0029","author":"The Clarion Trial 2022."},{"key":"2023021305292034600_CIT0030","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.119.040070","article-title":"Efficacy and safety of firibastat, a first-in-class brain aminopeptidase a inhibitor, in hypertensive overweight patients of multiple ethnic origins","volume":"140","author":"Ferdinand","year":"2019","journal-title":"Circulation"},{"key":"2023021305292034600_CIT0031","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.1073\/pnas.0402312101","article-title":"Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension","volume":"101","author":"Fournie-Zaluski","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023021305292034600_CIT0032","doi-asserted-by":"crossref","first-page":"13415","DOI":"10.1073\/pnas.96.23.13415","article-title":"Aminopeptidase A inhibitors as potential central antihypertensive agents","volume":"96","author":"Reaux","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023021305292034600_CIT0033","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1161\/HYPERTENSIONAHA.107.098772","article-title":"Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension","volume":"51","author":"Bodineau","year":"2008","journal-title":"Hypertension"},{"key":"2023021305292034600_CIT0034","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1042\/CS20130396","article-title":"A new strategy for treating hypertension by blocking the activity of the brain renin-angiotensin system with aminopeptidase A inhibitors","volume":"127","author":"Gao","year":"2014","journal-title":"Clin Sci (Lond)"},{"key":"2023021305292034600_CIT0035","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1161\/HYPERTENSIONAHA.119.14504","article-title":"Randomized dose-response study of the new dual endothelin receptor antagonist aprocitentan in hypertension","volume":"75","author":"Verweij","year":"2020","journal-title":"Hypertension"},{"key":"2023021305292034600_CIT0036","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJM199803193381202","article-title":"The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators","volume":"338","author":"Krum","year":"1998","journal-title":"N Engl J Med"},{"key":"2023021305292034600_CIT0037","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/jpet.116.234930","article-title":"Endothelin ETA receptor blockade, by activating ETB receptors, increases vascular permeability and induces exaggerated fluid retention","volume":"361","author":"Vercauteren","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"2023021305292034600_CIT0038","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(09)61500-2","article-title":"A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial","volume":"374","author":"Weber","year":"2009","journal-title":"Lancet"},{"key":"2023021305292034600_CIT0039","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1161\/HYPERTENSIONAHA.110.156976","article-title":"Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial","volume":"56","author":"Bakris","year":"2010","journal-title":"Hypertension"},{"key":"2023021305292034600_CIT0040","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","article-title":"Cardiovascular outcomes in patients with primary aldosteronism after treatment","volume":"168","author":"Catena","year":"2008","journal-title":"Arch Intern Med"},{"key":"2023021305292034600_CIT0041","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2023021305292034600_CIT0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00701.x","article-title":"Aldosterone in the development and progression of renal injury","volume":"66","author":"Hollenberg","year":"2004","journal-title":"Kidney Int"},{"key":"2023021305292034600_CIT0043","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1749-6632.2002.tb04415.x","article-title":"The pathophysiology of aldosterone in the cardiovascular system","volume":"970","author":"Rocha","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"2023021305292034600_CIT0044","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.tem.2008.01.006","article-title":"Primary aldosteronism: cardiovascular, renal and metabolic implications","volume":"19","author":"Rossi","year":"2008","journal-title":"Trends Endocrinol Metab"},{"key":"2023021305292034600_CIT0045","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.2174\/1381612825666190222144359","article-title":"Adverse effects of mineralocorticoid receptor antagonist administration","volume":"24","author":"Kallistratos","year":"2018","journal-title":"Curr Pharm Des"},{"key":"2023021305292034600_CIT0046","doi-asserted-by":"crossref","first-page":"105332","DOI":"10.1016\/j.phrs.2020.105332","article-title":"Aldosterone synthase inhibitors for cardiovascular diseases: a comprehensive review of preclinical, clinical and in silico data","volume":"163","author":"Lenzini","year":"2021","journal-title":"Pharmacol Res"},{"key":"2023021305292034600_CIT0047","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","article-title":"Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism","volume":"56","author":"Amar","year":"2010","journal-title":"Hypertension"},{"key":"2023021305292034600_CIT0048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms20133265","article-title":"Atrial natriuretic peptide: a molecular target of novel therapeutic approaches to cardio-metabolic disease","volume":"20","author":"Cannone","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2023021305292034600_CIT0049","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1152\/physrev.00022.2015","article-title":"Molecular physiology of membrane guanylyl cyclase receptors","volume":"96","author":"Kuhn","year":"2016","journal-title":"Physiol Rev"},{"key":"2023021305292034600_CIT0050","doi-asserted-by":"crossref","first-page":"II96","DOI":"10.1161\/01.HYP.8.6_Pt_2.II96","article-title":"Four-hour infusions of synthetic atrial natriuretic peptide in normal volunteers","volume":"8","author":"Biollaz","year":"1986","journal-title":"Hypertension"},{"key":"2023021305292034600_CIT0051","doi-asserted-by":"crossref","first-page":"R669","DOI":"10.1152\/ajpregu.00354.2019","article-title":"Long-term blood pressure lowering and cGMP-activating actions of the novel ANP analog MANP","volume":"318","author":"Chen","year":"2020","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2023021305292034600_CIT0052","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jacc.2009.04.080","article-title":"A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions","volume":"54","author":"McKie","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2023021305292034600_CIT0053","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1161\/HYPERTENSIONAHA.110.159210","article-title":"A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension","volume":"56","author":"McKie","year":"2010","journal-title":"Hypertension"},{"key":"2023021305292034600_CIT0054","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1161\/HYPERTENSIONAHA.121.17159","article-title":"First-in-human study of MANP: a novel ANP (atrial natriuretic peptide) analog in human hypertension","volume":"78","author":"Chen","year":"2021","journal-title":"Hypertension"},{"key":"2023021305292034600_CIT0055","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1161\/HYPERTENSIONAHA.122.18731","article-title":"Angiotensinogen suppression: a new tool to treat cardiovascular and renal disease","volume":"79","author":"Cruz-Lopez","year":"2022","journal-title":"Hypertension"},{"key":"2023021305292034600_CIT0056","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacbts.2021.04.004","article-title":"Antisense inhibition of angiotensinogen with IONIS-AGT-LRx: results of phase 1 and phase 2 studies","volume":"6","author":"Morgan","year":"2021","journal-title":"JACC Basic Transl Sci"},{"key":"2023021305292034600_CIT0057","article-title":"Durable reductions in circulating angiotensinogen and blood pressure six months after single doses of ALN-AGT, an RNA interference therapeutic targeting hepatic angiotensinogen synthesis, in hypertensive patients","volume":"144","author":"Huang","year":"2021","journal-title":"Circulation"},{"key":"2023021305292034600_CIT0058","year":"2022"},{"key":"2023021305292034600_CIT0059","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","article-title":"A controlled trial of renal denervation for resistant hypertension","volume":"370","author":"Bhatt","year":"2014","journal-title":"N Engl J Med"},{"key":"2023021305292034600_CIT0060","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/eurheartj\/ehu441","article-title":"Predictors of blood pressure response in the SYMPLICITY HTN-3 trial","volume":"36","author":"Kandzari","year":"2015","journal-title":"Eur Heart J"},{"key":"2023021305292034600_CIT0061","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.jacc.2015.08.018","article-title":"Impact of Lesion placement on efficacy and safety of catheter-based radiofrequency renal denervation","volume":"66","author":"Mahfoud","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2023021305292034600_CIT0062","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(22)01787-1","article-title":"Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial","author":"Bhatt","year":"2022","journal-title":"Lancet"},{"key":"2023021305292034600_CIT0063","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","article-title":"Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial","volume":"395","author":"Bohm","year":"2020","journal-title":"Lancet"},{"key":"2023021305292034600_CIT0064","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","article-title":"Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial","volume":"391","author":"Kandzari","year":"2018","journal-title":"Lancet"},{"key":"2023021305292034600_CIT0065","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1016\/j.jcin.2021.09.020","article-title":"Renal denervation for hypertension: a systematic review and meta-analysis of randomized, blinded, placebo-controlled trials","volume":"14","author":"Ahmad","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"2023021305292034600_CIT0066","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000357167","article-title":"Carotid baroreceptor stimulation: a potential solution for resistant hypertension","volume":"2","author":"Zhang","year":"2014","journal-title":"Interv Neurol"},{"key":"2023021305292034600_CIT0067","first-page":"1485","article-title":"Baroreceptors in the carotid and hypertension-systematic review and meta-analysis of the effects of baroreflex activation therapy on blood pressure","volume":"33","author":"Wallbach","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2023021305292034600_CIT0068","first-page":"RA1","article-title":"Arterial baroreceptors in the management of systemic hypertension","volume":"16","author":"Kougias","year":"2010","journal-title":"Med Sci Monit"},{"key":"2023021305292034600_CIT0069","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/01.CIR.39.1.48","article-title":"Diminished baroreflex sensitivity in high blood pressure","volume":"39","author":"Bristow","year":"1969","journal-title":"Circulation"},{"key":"2023021305292034600_CIT0070","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00392-019-01536-5","article-title":"Long-term effects of baroreflex activation therapy: 2-year follow-up data of the BAT Neo system","volume":"109","author":"Wallbach","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"2023021305292034600_CIT0071","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1161\/HYPERTENSIONAHA.109.140665","article-title":"Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients","volume":"55","author":"Heusser","year":"2010","journal-title":"Hypertension"},{"key":"2023021305292034600_CIT0072","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jash.2016.12.003","article-title":"An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems","volume":"11","author":"Wachter","year":"2017","journal-title":"J Am Soc Hypertens"},{"key":"2023021305292034600_CIT0073","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcin.2021.12.015","article-title":"Treatment of resistant hypertension with endovascular baroreflex amplification: 3-year results from the CALM-FIM study","volume":"15","author":"van Kleef","year":"2022","journal-title":"JACC Cardiovasc Interv"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpac111\/48614617\/hpac111.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/36\/2\/73\/49164031\/hpac111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/36\/2\/73\/49164031\/hpac111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T05:30:04Z","timestamp":1676266204000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/36\/2\/73\/6749842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":73,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,10,6]]},"published-print":{"date-parts":[[2023,2,13]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpac111","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,10,6]]}}}